US committee recommends HPV vaccine for boys

Roehr, Bob
November 2011
BMJ: British Medical Journal (Overseas & Retired Doctors Edition;11/5/2011, Vol. 343 Issue 7830, p927
Academic Journal
The article reports on a U.S. committee, which recommended mandatory quadrivalent vaccination to all boys in the U.S. against human papillomavirus (HPV) infection.


Related Articles

  • Immunogenicity of Quadrivalent HPV Vaccine Among Girls 11 to 13 Years of Age Vaccinated Using Alternative Dosing Schedules: Results 29 to 32 Months After Third Dose. LaMontagne, D. Scott; Thiem, Vu Dinh; Huong, Vu Minh; Tang, Yuxiao; Neuzil, Kathleen M. // Journal of Infectious Diseases;Oct2013, Vol. 208 Issue 8, p1325 

    Background. Immune response to quadrivalent human papillomavirus (HPV) vaccine delivered at 0, 2, and 6 months in young adolescent females plateaus around 24 months after immunization. Antibody levels >24 months postvaccination using extended dosing schedules is unknown.Methods. We conducted a...

  • Adolescent immunisation: the next big thing? Adam Finn // Archives of Disease in Childhood;Jun2011, Vol. 96 Issue 6, p497 

    The authors reflect on the initiation of the routine human papillomavirus (HPV) vaccine on the immunisation schedule for girls in Great Britain in 2008, which has strengthened the widespread immunisation of adolescents. The authors state that the immunisation programme has been successful with...

  • The human papillomavirus vaccine and risk of anaphylaxis. Halsey, Neal A. // CMAJ: Canadian Medical Association Journal;9/9/2008, Vol. 179 Issue 6, p509 

    The author reflects on a study which reveals higher than expected rates of apparent anaphylaxis following vaccination with the quadrivalent human papillomavirus (HPV) vaccine in children in Australia. He points out that the report failed to determine the causes of anaphylactoid reactions among...

  • Study to determine safety, efficacy of the new nine-valent HPV vaccine.  // Infectious Diseases in Children;Jan2008, Vol. 21 Issue 1, p11 

    The article reports that researchers at the Medical College of Georgia will test the quadrivalent human papillomavirus vaccine (HPV) against three different doses of the investigational HPV to determine the safety and efficacy of the new nine-valent vaccine. Doctor Daron Ferris, family medicine...

  • CORRECTIONS.  // Annals of Internal Medicine;4/5/2011, Vol. 154 Issue 7, p508 

    Corrections to articles "Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States" and one regarding the recommended adult immunization guidelines in the U.S. in 2011 are presented.

  • The Risks and Benefits of HPV Vaccination. Haug, Charlotte // JAMA: Journal of the American Medical Association;8/19/2009, Vol. 302 Issue 7, p795 

    The author comments on the risks and beneficial effects of human papillomavirus (HPV) vaccine. She examines the theory behind the vaccine, and argues on the right vaccine that could prevent HPV infection. She discusses the two papers published which present significant data that may influence...

  • Why HIV Virions Have Low Numbers of Envelope Spikes: Implications for Vaccine Development. Schiller, John; Chackerian, Bryce // PLoS Pathogens;Aug2014, Vol. 10 Issue 8, p1 

    The article attempts to determine why HIV have low numbers of envelope spikes per virion. Topics discussed include the importance of understanding how a virus counteract the antibody response of the host, the ability of human papillomavirus (HPV) vaccines to induce neutralizing antibody...

  • Analysis of peripheral blood immune cells after prophylactic immunization with HPV-16/18 ASO4-adjuvanted vaccin. Hus, Iwona; Gonet-Sebastianka, Joanna; Surdacka, Agata; Bojarska-Junak, Agnieszka; RoliƄski, Jacek // Advances in Hygiene & Experimental Medicine / Postepy Higieny i ;2015, Vol. 69, p543 

    Persistent infection with oncogenic types of human papillomavirus (HPV) is a causal factor for more than 99% of cervical cancers. Recently, prophylactic vaccines have been developed to prevent infections with cancer-associated HPV types (HPV16 and HPV18). The aim of this study was to analyze the...

  • Choice of cancer vaccine is branded a missed opportunity by charities. Kmietowicz, Zosia // BMJ: British Medical Journal (International Edition);6/28/2008, Vol. 336 Issue 7659, p1456 

    The article discusses how health charities are criticizing the adoption of the drug Cervarix into national immunisation initiatives in Great Britain. Cervarix, developed by the pharmaceutical firm GlaxoSmithKline is designed to vaccinate women against human papillomaviruses, which can cause...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics